Wells Fargo Reiterates Overweight Rating on Avidity Biosciences (RNA)

June 12, 2024 5:55 AM UTC Send to a Friend
Wells Fargo analyst Yanan Zhu reiterated an Overweight rating and $50.00 price target on Avidity Biosciences (NASDAQ: RNA).The analyst comments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login